AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
← catalyst calendarNCT06106945 · readout in 362 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
226estimated
Sites
43
Countries
Australia, Brazil, Canada +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-05 | actual | When the study began enrolling |
| Primary completion | 2027-08-16 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-16 | estimated | The whole study's end, after follow-up |
| First posted | 2023-10-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Myeloma
Interventions
- Drug: AZD0305
- Drug: Elranatamab
- Drug: Pomalidomide
- Drug: Dexamethasone
Primary outcomes
what the primary-completion date above is the date OFOccurrence of dose-limiting toxicity (DLT), as defined in the protocol (Phase Ia dose escalation only)
measured From first dose of AZD0305 until the end of Cycle 1. Cycle 1 (the DLT assessment period is 21 days for Module 1 Group A and 28 days for Module 1 Group B, Module 2, and Module 3)
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured From time of Informed consent to 30 days post end of treatment
Frequency of dose modifications, dose delays, and treatment discontinuations due to AEs (Module 2 and Module 3)
measured From first dose of study treatment until End of treatment (EOT), assessed up to approximately 2 years (each cycle is 28 days)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed